Altamira Therapeutics Ltd. (CYTO)
After hours:
| Previous close | 1.6000 |
| Open | 1.5400 |
| Bid | 1.6500 x 100 |
| Ask | 1.7900 x 100 |
| Day's range | 1.5100 - 1.7700 |
| 52-week range | 1.3500 - 28.4000 |
| Volume | |
| Avg. volume | 1,190,587 |
| Market cap | 3.786M |
| Beta (5Y monthly) | 2.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.1800 |
| Earnings date | 10 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medicationStudy outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeu
- GlobeNewswire
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
Presenting Companies to Host 25-Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minute presentations by public
- GlobeNewswire
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new applicationsPartnering of legacy assets underway as Company transitions to focused RNA delivery technology providerAchieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debtFinished year with shareholders’ equity of CHF 6.5 million, improved by CHF 14.8 million HAMILTON, BERMUDA
